Phenotypes Associated with This Genotype

Genotype
MGI:3769118

• Allelic Composition: Irf1^tm1Mak/Irf1^tm1Mak
• Genetic Background: B6.129S2-Irf1^tm1Mak/J

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

increased susceptibility to xenobiotic induced morbidity/mortality ( J:91927 )

• increase in mortality following a single dose of N-methyl-N-nitrosourea (MNU) compared to similarly treated wild-type controls

• treatment with recombinant IL12 significantly improves survival of MNU treated mice

homeostasis/metabolism

abnormal circulating alanine transaminase level ( J:111090 )

• when subjected to warm ischemia/reperfusion (I/R), 60 minutes of warm hepatic ischemia followed by 6 hours of reperfusion significantly increase serum ALT levels in controls, but levels in treated mutants are ~60% lower than I/R-treated wild-type mice

increased susceptibility to xenobiotic induced morbidity/mortality ( J:91927 )

• increase in mortality following a single dose of N-methyl-N-nitrosourea (MNU) compared to similarly treated wild-type controls

• treatment with recombinant IL12 significantly improves survival of MNU treated mice

increased incidence of tumors by chemical induction ( J:91927 )

• following a single dose of MNU most mice develop massive lymphoid neoplasias

• treatment with recombinant IL12 reduces the incidence of lymphomas in MNU treated mice

immune system

abnormal lymphocyte physiology ( J:91927 )

• impairment in the ability to produce IFNG in response to Con A stimulation

• IL12 treatment can rescue the impairment in IFNG production

decreased interferon-gamma secretion ( J:91927 )

• by lymphocytes following Con A stimulation

• IL12 treatment can rescue the impairment in IFNG production

neoplasm

increased incidence of tumors by chemical induction ( J:91927 )

• following a single dose of MNU most mice develop massive lymphoid neoplasias

• treatment with recombinant IL12 reduces the incidence of lymphomas in MNU treated mice

increased lymphoma incidence ( J:91927 )

• following a single dose of MNU compared to similarly treated wild-type controls

hematopoietic system

abnormal lymphocyte physiology ( J:91927 )

• impairment in the ability to produce IFNG in response to Con A stimulation

• IL12 treatment can rescue the impairment in IFNG production